Retatrutide is an investigational medication being studied as a triple-agonist, meaning it targets three hormone receptors involved in metabolism and appetite regulation: GLP-1, GIP and glucagon
doi: 10.1038/s41531-020-00124-z 145 Santos-GarcaD.de FonticobaD
A comprehensive treatment involving a cleft surgeon, otolaryngologist, geneticist, speech pathologist, orthodontist and others are required at multiple stages right from infancy to adulthood
Lindholm LH, Ibsen H, Dahlof B, et al
According to the manufacturer, cerebrolysin is described as the sole pharmacological agent supported by evidence for brain trauma recovery in certain guidelines
This condition is caused by reduced blood flow to the leg, which can decrease mobility, physical performance and life quality